S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
Log in

Onconova Therapeutics Stock Forecast, Price & News

-0.05 (-6.02 %)
(As of 01/19/2021 12:00 AM ET)
Today's Range
Now: $0.78
50-Day Range
MA: $0.49
52-Week Range
Now: $0.78
Volume32.31 million shs
Average Volume61.76 million shs
Market Capitalization$161.26 million
P/E RatioN/A
Dividend YieldN/A
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. The company has a license agreement with SymBio Pharmaceuticals Limited; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of ON 123300 in Greater China. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Onconova Therapeutics logo


Overall MarketRank

1.50 out of 5 stars

Analyst Opinion: 3.1Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ONTX



Sales & Book Value

Annual Sales$2.18 million
Book Value$0.08 per share


Net Income$-21,500,000.00
Net Margins-11,997.55%


Market Cap$161.26 million
Next Earnings Date3/23/2021 (Estimated)
OptionableNot Optionable
-0.05 (-6.02 %)
(As of 01/19/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ONTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ONTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions

How has Onconova Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Onconova Therapeutics' stock was trading at $0.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ONTX shares have increased by 116.7% and is now trading at $0.7802.
View which stocks have been most impacted by COVID-19

Is Onconova Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Onconova Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONTX, but not buy additional shares or sell existing shares.
View analyst ratings for Onconova Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Onconova Therapeutics?

Wall Street analysts have given Onconova Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Onconova Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Onconova Therapeutics' next earnings date?

Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 23rd 2021.
View our earnings forecast for Onconova Therapeutics

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics, Inc. (NASDAQ:ONTX) announced its quarterly earnings results on Thursday, November, 12th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by $0.01. The biopharmaceutical company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $4.10 million. Onconova Therapeutics had a negative net margin of 11,997.55% and a negative return on equity of 161.10%.
View Onconova Therapeutics' earnings history

When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?

Shares of Onconova Therapeutics reverse split before market open on Wednesday, September 26th 2018. The 1-15 reverse split was announced on Tuesday, September 25th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 25th 2018. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for ONTX?

4 brokerages have issued twelve-month target prices for Onconova Therapeutics' stock. Their forecasts range from $1.25 to $2.00. On average, they expect Onconova Therapeutics' stock price to reach $1.52 in the next twelve months. This suggests a possible upside of 94.4% from the stock's current price.
View analysts' price targets for Onconova Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Onconova Therapeutics' key competitors?

What other stocks do shareholders of Onconova Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM).

Who are Onconova Therapeutics' key executives?

Onconova Therapeutics' management team includes the following people:
  • Dr. Steven M. Fruchtman, CEO, Pres & Director (Age 69, Pay $722.51k)
  • Dr. Manoj Maniar, Sr. VP of Product Devel. (Age 57, Pay $565.31k)
  • Dr. Richard Charles Woodman M.D., Chief Medical Officer and Sr. VP of R&D (Age 65, Pay $405.31k)
  • Dr. Ramesh Kumar, Advisor (Age 64, Pay $1.21M)
  • Mr. Mark Patrick Guerin, Chief Financial Officer (Age 51)
  • Mr. Abraham N. Oler J.D., M.B.A., Esq., CFA, Sr. VP of Corp. Devel. & Gen. Counsel (Age 44)

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

How do I buy shares of Onconova Therapeutics?

Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Onconova Therapeutics' stock price today?

One share of ONTX stock can currently be purchased for approximately $0.78.

How big of a company is Onconova Therapeutics?

Onconova Therapeutics has a market capitalization of $161.26 million and generates $2.18 million in revenue each year. The biopharmaceutical company earns $-21,500,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. Onconova Therapeutics employs 17 workers across the globe.

What is Onconova Therapeutics' official website?

The official website for Onconova Therapeutics is www.onconova.com.

How can I contact Onconova Therapeutics?

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.